London startup to trial drug preventing cytokine storm in cancer patients
Executive summary: Poolbeg Pharma is set to trial a drug in six NHS hospitals to prevent cytokine storm, a severe immune reaction, in cancer patients undergoing immunotherapy. If proven effective, the drug could reduce mortality and complications, lower treatment costs, and create a new market niche for adjunctive oncology therapies.
Who is involved: Poolbeg Pharma, NHS hospitals, cancer patients, oncology investors.
Likely next: Phase 1 safety data expected within months, followed by Phase 2 trials and regulatory review pending MHRA approval.
Poolbeg Pharma will begin a trial of a drug in six NHS hospitals that aims to prevent cytokine release syndrome, a life‑threatening side‑effect of cancer immunotherapy. The trial will assess safety and early efficacy in patients receiving checkpoint inhibitors. Success could introduce a new adjunct therapy and generate a new revenue stream for the startup.
What's next — scenarios
Full Clinical Success (25%)
Poolbeg Pharma secures high-valuation Series B funding or M&A interest from Big Pharma.
- Positive Phase I safety data
- High recruitment rates in first 3 months
Delayed/Limited Efficacy (45%)
Startup shifts focus to niche patient populations, extending cash runway requirement.
- Significantly higher-than-expected adverse events
- Slow patient enrollment due to protocol complexity
Regulatory/Trial Failure (30%)
Binary outcome leads to complete loss of investment capital.
- Severe adverse events in control group
- Inability to demonstrate statistically significant safety profile
What to watch
- NHS recruitment milestones (next 60 days)
- First interim safety report from trial sites (next 90 days)
- Any published protocol details in peer-reviewed journals (next 90 days)
Timeline
- — London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’ (The Guardian — Business)
Analysis — what this means
Likely next events
- Phase 1 safety results in Q4 2026
- Submission of Phase 2 protocol early 2027
- Regulatory review by MHRA
Sectors affected
- Oncology
- Immunotherapy
- Pharmaceuticals
Regulatory implications
- Requirement for MHRA approval
- NHS cost‑effectiveness assessment
- Possibility of fast‑track designation
Historical parallels
- Development of anti‑TNF biologics for rheumatology
- Use of GLP‑1 agonists for weight loss
- Early trials of checkpoint inhibitors
Sources
- London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’ — The Guardian — Business
Related cases
- NICE recommends systematic NHS funding for Bridge to Life's VitaSmart hypothermic oxygenated perfusion system
- NHS pension administration error leaves retiree declared deceased and without payments
- Implant shows 75% pain relief in refractory angina, highlighting near-term medical device investment opportunities
- Decade-long UK study reveals men with heart disease face significantly higher cancer incidence and mortality, highlighting gender-specific health risks with implications for healthcare costs and insurance